Therapeutic Response

HER2-positive status confers therapeutic sensitivity to Carboplatin in combination with Docetaxel and Trastuzumab in patients with Invasive Breast Carcinoma.

Statements

Source and description
Trastuzumab Subcutaneous 21 days - Early Breast Cancer. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with adjuvant chemotherapy consisting of carboplatin and docetaxel for reimbursement as a treatment option for the treatment of HER2 positive early breast cancer.
Herceptin (trastuzumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized trastuzumab in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin for the treatment of adult patients with HER2 positive early breast cancer (EBC). The production information for trastuzumab notes that trastuzumab should only be used in patients with metastatic or early breast cancer whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.